دورية أكاديمية
Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.
| العنوان: | Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib. |
|---|---|
| المؤلفون: | da Mota LM; Hospital Universitário de Brasília, Universidade de Brasília (UnB), Brasília, DF, Brasil; Programa de Pós-graduação em Ciências Médicas, Faculdade de Medicina, Universidade de Brasília (UnB), Brasília, DF, Brasil. Electronic address: licia@unb.br., Cruz BA; Biocor Instituto, Nova Lima, MG, Brasil., de Albuquerque CP; Serviço de Reumatologia, Hospital Universitário de Brasília, Universidade de Brasília (UnB), Brasília, DF, Brasil., Gonçalves DP; Serviço de Reumatologia, Hospital Universitário Walter Cantídio, Fortaleza, CE, Brasil; Serviço de Reumatologia, Hospital Geral Dr. César Cals, Fortaleza, CE, Brasil; Programa de Residência Médica em Reumatologia, Hospital Geral Dr. César Cals, Fortaleza, CE, Brasil., Laurindo IM; Universidade de São Paulo (USP), São Paulo, SP, Brasil; BiobadaBrasil, Brasil., Pereira IA; Disciplina de Reumatologia, Universidade do Sul de Santa Catarina (Unisul), Florianópolis, SC, Brasil; Núcleo de Reumatologia, Hospital Universitário, Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brasil., de Carvalho JF; Hospital Aliança, Salvador, BA, Brasil., Pinheiro Gda R; Disciplina de Reumatologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro (Uerj), Rio de Janeiro, RJ, Brasil., Bertolo MB; Disciplina de Reumatologia, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brasil; Departamento de Clínica Médica, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brasil., Pinto MR; Ambulatório de Artrite Reumatoide, Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil; Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil., Louzada-Junior P; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brasil., Xavier RM; Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil; Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil., Giorgi RD; Serviço de Reumatologia, Hospital do Servidor Público Estadual Francisco Morato de Oliveira (HSPE-FMO), São Paulo, SP, Brasil., Lima RA; Serviço de Reumatologia, Hospital de Base do Distrito Federal, Brasília, DF, Brasil. |
| المصدر: | Revista brasileira de reumatologia [Rev Bras Reumatol] 2015 Nov-Dec; Vol. 55 (6), pp. 512-21. Date of Electronic Publication: 2015 Sep 26. |
| نوع المنشور: | Journal Article; Practice Guideline; Review |
| اللغة: | English; Portuguese |
| بيانات الدورية: | Publisher: Elsevier Editora Country of Publication: Brazil NLM ID: 0404256 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1809-4570 (Electronic) Linking ISSN: 04825004 NLM ISO Abbreviation: Rev Bras Reumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2009- : São Paulo : Elsevier Editora Original Publication: Sao Paulo : Sociedade Brasileira De Reumatologia |
| مواضيع طبية MeSH: | Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Piperidines/*therapeutic use , Pyrimidines/*therapeutic use , Pyrroles/*therapeutic use, Brazil ; Drug Therapy, Combination ; Humans ; Methotrexate/therapeutic use ; Rheumatology ; Societies, Medical ; Treatment Failure |
| مستخلص: | In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database. After this review, a text was produced, answering questions in Pico structure, considering efficacy and safety issues of tofacitinib use for RA treatment in different scenarios (such as first-line treatment after failure with methotrexate [MTX] or other conventional synthetic DMARDs after failure with biological therapy). Based on existing evidence, and considering the available data on efficacy, safety and cost of medications available to treat the disease in Brazil, the RA Commission of SBR, after a process of discussion and voting on proposals, established the following position on the use of tofacitinib for treatment of RA in Brazil: "Tofacitinib, alone or in combination with MTX, is an alternative for RA patients with moderate or high activity after failure of at least two different synthetic DMARDs and one biological DMARD." The level of agreement with this recommendation was 7.5. This position may be reviewed in the coming years, in the face of a greater experience with the use of this medication. (Copyright © 2015 Elsevier Editora Ltda. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Artrite reumatoide; Brasil; Brazil; Rheumatoid arthritis; Tofacitinib; Tofacitinibe; Tratamento; Treatment |
| المشرفين على المادة: | 0 (Antirheumatic Agents) 0 (Piperidines) 0 (Pyrimidines) 0 (Pyrroles) 87LA6FU830 (tofacitinib) YL5FZ2Y5U1 (Methotrexate) |
| تواريخ الأحداث: | Date Created: 20151013 Date Completed: 20180515 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.rbr.2015.08.004 |
| PMID: | 26456224 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1809-4570 |
|---|---|
| DOI: | 10.1016/j.rbr.2015.08.004 |